Vertex Pharmaceuticals, Inc. (VRTX) Misses Q2 EPS by 13c; Revises Revenues
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
EPS Growth %: 0.0%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of $0.46, $0.13 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $418.3 million versus the consensus estimate of $472.16 million.
Vertex today revised guidance for full-year 2012 INCIVEK net revenues. The company expects full-year 2012 INCIVEK net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Vertex today revised guidance for full-year 2012 INCIVEK net revenues. The company expects full-year 2012 INCIVEK net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
- JPMorgan Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
